Back to search

Article

Congenital Neutropenia With Specific Granulocyte Deficiency Caused By Novel Double Heterozygous SMARCD2 Mutations: is there a benefit of thrombopoietin receptor agonist therapy?

2024-01-31

Abstract excerpt

SMARCD2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily D, member 2) is critical for myelopoiesis. Recently, bi-allelic SMARCD2 mutations have been reported in five children causing autosomal recessive congenital neutropenia with specific granulocytes deficiency (CN-SGD); a syndrome resulting in G-CSF resistant neutropenia, recurrent infections and dysplastic myelopoiesis. We...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
840fa5d4-6036-596d-ad3b-658ee46f8c44
DOI
10.22541/au.170669090.00774557/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Congenital Neutropenia With Specific Granulocyte Deficiency Caused By Novel Double Heterozygous SMARCD2 Mutations: is there a benefit of thrombopoietin receptor agonist therapy?DOI 10.22541/au.170669090.00774557/v1
Select a neighboring publication to make it the new centre.